NCT06833281View on ClinicalTrials.gov

Extension Study of Participants From SPG302-ALZ-101

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Alzheimer's Disease

Interventions

DRUG

SPG302

small synthetic molecule

Trial Locations (2)

2010

St. Vincent's Hospital, Sydney

5000

Flinders Medical Center, Adelaide

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Spinogenix

INDUSTRY